VEGFA and neoplasm: The concurrent neutralization of VEGFA and ANGPT2 by a bispecific antibody promotes vascular regression, tumor necrosis, blood vessel normalization, and increases cytotoxic T cell infiltration in both genetically engineered and transplant tumor models, including metastatic breast cancer, pancreatic neuroendocrine tumor, and melanoma.